SAN DIEGO,
Nov. 21, 2017
/PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
will present at the 29th Annual Piper Jaffray
Healthcare Conference at 12:00 p.m.
ET on Tuesday, Nov. 28, 2017,
in New York City. Timothy P. Coughlin, Vice President
Finance of Neurocrine Biosciences, will present at the
conference.
The live presentation will be webcast and may be accessed on the
Company's website at http://www.neurocrine.com. A replay of the
presentation will be available on the website approximately one
hour after the conclusion of the event and will be archived for one
month.
About Neurocrine Biosciences, Inc.
Neurocrine Biosciences is a San Diego based
biotechnology company focused on neurologic, psychiatric and
endocrine related disorders. The Company markets
INGREZZA® (valbenazine) capsules in the United
States for the treatment of adults with tardive
dyskinesia. INGREZZA is a novel, selective vesicular monoamine
transporter 2 (VMAT2) inhibitor, and is the first FDA approved
product indicated for the treatment of adults with tardive
dyskinesia. The Company's three late-stage clinical programs
are: elagolix, a gonadotropin-releasing hormone antagonist for
women's health that is partnered with AbbVie Inc.; opicapone,
a novel, once-daily, peripherally-acting, highly-selective
catechol-o-methyltransferase inhibitor under investigation as
adjunct therapy to levodopa in Parkinson's patients; and INGREZZA,
a novel, once-daily, selective VMAT2 inhibitor under investigation
for the treatment of Tourette syndrome.
Neurocrine Biosciences, Inc. news releases are available
through the Company's website via the internet at
http://www.neurocrine.com.
View original
content:http://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-the-29th-annual-piper-jaffray-healthcare-conference-300559765.html
SOURCE Neurocrine Biosciences, Inc.